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Despite the impressive advancements in the treatment 
of psoriasis over the past two decades, there is still a 
need for further improvement. As previously shown in 
the literature, genistein (5,7-dihydroxy-3-(4-hydroxyphe-
nyl)chromen-4-one), naturally occurring plant compound 
displays multidirectional action, also in relation to alle-
viating psoriasis symptoms. In this work we focused our 
attention on genistein impact on expression of genes 
when treating moderate-to-severe psoriasis patients. 
Testing the effects of this isoflavone on transcript levels 
in both skin specimens and peripheral blood cells of four 
psoriatic subjects, we found that this compound modu-
lated activities of genes coding for anti-psoriatic mem-
bers and anti-inflammatory mediators of inflammation. 
It impairs the activity of certain genes which are overex-
pressed in psoriasis, while stimulating the expression of 
other transcripts that are repressed in dermatosis.
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INTRODUCTION
Choice of the suitable medical handling depends on 
the severity of psoriasis. If skin lesions are mild and lo-
calised, only topical treatment is applied. At a more ad-
vanced stage of psoriasis, systemic therapy is initiated, 
according to clinical recommendations. Another ap-
proach of general treatment is suppressing an excessive 
immune response by using the selected, classic drugs. 
Over the past decade, biological drugs have been devel-
oped, which are an additional treatment option for mod-
erate and severe psoriasis. Unfortunately, 1/3 of patients 
do not respond to biological therapy, and some lose the 
initial response due to the development of antidrug an-
tibodies (ADA) (Hsu et al., 2014) Alternatives are small-
molecule drugs and organic compounds targeting the 
key molecules of selected signalling pathways. Another 
group of drugs are the so-called biosimilars, which do 
not show clinically relevant differences in purity, safety 
and potency relative to a reference therapeutic product. 
Three of them obtained approval from the Food and 
Drug Administration (FDA) in 2016; however, further 
studies are necessary (Gupta et al., 2014; Lee et al., 2013). 
Treatments used in psoriasis are still of risk of toxicity 
and adverse reactions. Thus, alternative, safe, and if only 
possible, natural therapeutic agents are desired.
Bioactive plant-derived metabolites such as flavo-
noids, have been studied as potential agents in medicine 
for many years (Molyneux et al., 2007; Nakamura et al., 
2010). They are ubiquitous plant secondary products, 
well-known for their antioxidant and anti-inflammatory 
properties (Chamcheu et al., 2017; Nijveldt et al., 2001, 
Pazyar et al., 2015). Among these compounds, genistein 
(5,7-dihydroxy-3-(4-hydroxyphenyl) chromen-4-one), the 
major metabolite of soy, is considered as regulator of in-
flammatory responses in the skin, and therefore can con-
sequently be useful in the treatment of atopic dermatitis, 
vitiligo and psoriasis (Korkina et al., 2012). Importantly, 
genistein is a potent inhibitor of the production of pro-
inflammatory factors, such as IL1, IL6, and TNF-alpha 
by modulating the nuclear factor kappa B (NF-κB) and 
phosphoinositide 3 kinase/protein kinase B (PI3K/Akt) 
pathways in macrophages and endothelial cells. Defin-
ing molecular bases of genistein biological action and 
function in psoriasis is essential to evaluate safety of 
this composite and to develop finest therapeutic proce-
dures. Therefore, in this study we aimed at determining 
the pattern of isoflavone genistein impact of on genes’ 
expression in the clinical material, skin specimens and 
blood samples, derived from psoriatic patients.
MATERIALS AND METHODS
Ethical agreement and patient profile. This multi-
center, randomized clinical study was conducted in Po-
land. Institutional review boards at each study site ap-
proved the protocol, and all tested patients provided 
written informed consent. The investigation was con-
ducted in compliance with the Declaration of Helsin-
ki. The study no. GE/BF/09/13 was registered in the 
Central Register of Clinical Trials (CEBK) and Inde-
pendent Ethic Committee under the numbers UR.DBL.
BLE.475.0110.2014 and KB/910/13, respectively. Pa-
tients were eligible for study enrolment if they were aged 
18 years or older with active, clinically stable mild to 
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moderate chronic plaque psoriasis for ≥12 months prior 
to the first dose of the study drug. Patients were required 
to have a Psoriasis Area and Severity Index (PASI) score 
≤12, a Physician’s Global Assessment (PGA) score of 2 
or 3, and <10% Body Surface Area (BSA) psoriasis in-
volvement (Table 1). Patients were required to have ade-
quate haematological, renal, and hepatic function.
Genistein dosing, skin biopsies and blood sam-
pling. Genistein dosing and blood and skin biopsy 
preparation for gene profile evaluation: Patients were 
screened 1–21 days prior to the administration of the 
first dose of genistein or placebo on day 0. They were 
enrolled in this multicenter, double-blind, placebo-con-
trolled study, randomized (1:1) to treat with oral film-
coated tablets in one of two treatment regimens: (1) gen-
istein 75 mg or 150 mg per day or (2) placebo. Genistein 
(GEN) was synthesised at the Pharmaceutical Research 
Institute (Warsaw, Poland) (Table 1).
Samples of blood and skin biopsy were collected at 
two time points: baseline (Day 0) and 56 days (Day 56) 
of treatment. Biopsies were taken under local anaesthesia 
from 4 psoriatic participants. One 3 mm punch biopsy 
was obtained from psoriatic plaque skin (PP) and the 
other psoriatic normal skin (PN), sampled at least 10 cm 
away from any active plaque. Venous blood for gene 
expression profiling was collected by phlebotomy with 
a butterfly needle into PAXgene tubes. The first drawn 
tube from all patients was ejected, as suggested by the 
PAXgene procedure.
RNA processing
Skin biopsies. After removal from the skin, biop-
sies were snap-frozen in liquid nitrogen and stored at 
–80°C until use. The isolation of total RNA from pso-
riatic plaque and psoriatic normal skin (unaffected skin) 
biopsies was carried out using an RNA Fibrous Tissues 
Mini Kit (Qiagen, Germany) and Trizol (Ambion, USA), 
according to the manufacturer’s protocol. Blood. Total 
RNA was extracted from the whole blood of patients 
and control subjects using the PAXgene Blood RNA 
Kit (Qiagen, Germany) according to the manufacturer’s 
protocol. Analysis of RNA quality and quantity was per-
formed using the Nanodrop (ThermoFisher Scientific, 
USA) and RNA 6000 Nano Assay on the Agilent 2100 
Bioanalyser (Agilent Technologies, USA).
Real-time quantitative reverse transcription PCR (real-
time qRT-PCR)
The reverse transcription reaction was performed on 
an RNA template and cDNA was synthesised using the 
Transcriptor First-Strand cDNA Synthesis Kit (Roche 
Applied Science, USA) according to the manufacturer’s 
protocols. All probes for real-time qRT-PCR are sum-
marised in Table 2. The 63 genes were selected on the 
basis of the classification criteria referring to the most 
up-to-date scientific reports describing a list of genes 
with significantly differentiated activity obtained in both 
in vitro and in vivo analyses when studying psoriatic phe-
notypes, stated at least a couple of times in unrelated lit-
erature sources (Bocheńska et al., 2017; Coda et al., 2012; 
Emmerson et al., 2010; Galluzzo et al., 2018; González 
et al., 2011; Gudjonsson et al., 2009; Gudjonsson et al., 
2010; Martin et al., 2013; Tian et al., 2012). Except for 
published lists of genes, we also studied and reviewed 
the psoriasis-associated genes database (PAGD), as well 
as the database of genes associated with psoriasis (db-
GAP). Thus, applied real-time qRT-PCR assays were 
obtained for genes encoding proteins involved in lipid 
metabolism, antimicrobial defences, epidermal differen-
tiation and the control of cutaneous vasculature. As ke-
ratinocytes at inflammatory sites of the epidermis induce 
the abnormal expression of cytokines and chemokines, 
leading to the infiltration of T cells or leukocytes (Tian 
et al., 2012; Dowlatshahi et al., 2013), we also examined 
the effects of genistein on the expression of selected 
chemokine genes.
The pre-plated PCR assays contained target specific 
primers and a matching probe from the Universal Probe 
Library (UPL). Real-time qRT-PCR was run using the 
Light Cycler 480 II detection system (Roche Applied 
Science, USA) and the quantification of gene expres-
sion was determined by the comparative DDCt meth-
od. The analysis of transcripts driven from the tested 
genes showed those in which expression was identified 
as being different by at least 0.7- and 1.3-fold changes 
(p<0.05): (skin samples) in lesional involved psoriatic 
Table 1. Clinical trial design.
Groups identified for study
Trancription analysis
Placebo 75 mg GEN 150 mg GEN
n=1 n=2 n=1
Patient u.11 u.09 u.12 u.15
Age 34 51 60 39
Sex male male female female
Race caucasian caucasian caucasian caucasian
Weight (kg) 94 98 67 80
BMI 29.7 33.5 26.5 29.4
PASI
Day 0 7.0 3.6 11.7 9.2
Day 56 8.4 8.8 5.2 16.8
BSA
Day 0 3.0 1.5 9.75 7.5
Day 56 8.5 2.5 9.0 10.5
PGA
Day 0 2 2 2 2
Day 56 2 3 2 3
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Table 2. Sequences of primer and probe numbers applied for real-time qRT-PCR.
Gene symbol Forward sequence Reverse sequence UPL probe no. Skin PBCs
ACACB GGGAGAGAACCGGGAAGA CCTCGGATGGACAGTTCCT 77 ‡
AKT1 GCAGCACGTGTACGAGAAGA GGTGTCAGTCTCCGACGTG 45 ‡
CAT CGCAGTTCGGTTCTCCAC GGGTCCCGAACTGTGTCA 67 ‡
CCL2 AGTCTCTGCCGCCCTTCT GTGACTGGGGCATTGATTG 83 ‡
CCL3 GCTGACTACTTTGAGACGAGCA GCTTCGCTTGGTTAGGAAGA 125 ‡
CCL4 TGCTTCTCCATGAGACACATCT AAAGATTAAATTAAGAGAAGGGACAGG 55 ‡ ‡
CCL5 CCTCATTGCTACTGCCCTCT GGTGTGGTGTCCGAGGAATA 16 ‡ ‡
CCL19 CACTACCTTCTCATCAAGGATGG CCCCTCAGTGTGGTGAACA 40 ‡
CXCL1 CATCGAAAAGATGCTGAACAGT CTTCAGGAACAGCCACCAGT 52 ‡ ‡
CXCL6 CACGAGGAAACCAAAGTGC GGGAGGCTCATAGTGGTCAA 65 ‡
CXCL10 AAAAGGTATGCAATCAAATCTGC AAGAATTTGGGCCCCTTG 86 ‡ ‡
DEFB4A TCAGCCATGAGGGTCTTGTA GGATCGCCTATACCACCAAA 35 ‡ ‡
EGFR CAGCCACCCATATGTACCATC AACTTTGGGCGACTATCTGC 42 ‡
FABP5 GCAGACCCCTCTCTGCAC TCGCAAAGCTATTCCCACTC 11 ‡
FADS1 CATCAACATGCATCCCTTCTT TTTGTGCTGGTGGTTGTACG 60 ‡
FOSL1 AGGAACTGACCGACTTCCTG TCTGCAGCTCCTCAATCTCTC 26 ‡
FOXC1 TGCTTTTCAGAGACCTGCTTT GCAAGGAAGAAGGCAAGAGA 52 ‡
FOXO1 GCAGCCAGGCATCTCATAAC GCATGTCCAGGGTGGGTAT 33 ‡
GATA3 CTCATTAAGCCCAAGCGAAG GTCTGACAGTTCGCACAGGA 108 ‡
GJB2 CAAGAACGTGTGCTACGATCA GCGTGGACACGAAGATCAG 60 ‡
IL1A GAATGACGCCCTCAATCAAA TGATGACTTATAAGCACCCATGTC 66 ‡ ‡
IL1B AGCTGATGGCCCTAAACAGA TCGGAGATTCGTAGCTGGAT 85 ‡ ‡
IL1RN TGCCTGTCCTGTGTCAAGTC TCTCGCTCAGGTCAGTGATG 54 ‡ ‡
IL2 TGTTCAAGAGTTCCCTATCACTCTC GCAAGACAGGAGTTGCATCC 51 ‡
IL6 ACCGGGAACGAAAGAGAAG GAAGGCAACTGGACCGAAG 133 ‡ ‡
IL8 TAGCCAGGATCCACAAGTCC CTGTGAGGTAAGATGGTGGCTA 98 ‡ ‡
IL10 CTGCCTAACATGCTTCGAGA GTCCAGCTGATCCTTCATTTG 161 ‡ ‡
IL11 AGCTGCAAGGTCAAGATGGT AGATTGTTTCCAGTTTGCTATGG 76 ‡
IL12A CACTCCCAAAACCTGCTGAG TCTCTTCAGAAGTGCAAGGGTA 50 ‡ ‡
IL17A CCTATAAGCAAAACAAAGCATGTC CGAGAACTTGGAATTTTGGGTA 85 ‡
IL18 AAGGAATTGTCTCCCAGTGC CCTCTTCCCGAAGCTGTGTA 71 ‡ ‡
IL20 ACAGCCAGATTCTGAGTCACTTT AGCAGCATCACTTTCCTCCT 25 ‡ ‡
IL20RA GCGTACACGTGGAGTCCTTC AGCCTTGAACTCTGATGATTGAT 81 ‡
IL23A GAAGCTGCTAGGATCGGATATTT AGTAGGGAGGCATGAAGCTG 32 ‡ ‡
IL24 GCTGCAGCAGGAGGTTCT GCAGGGTGTGGACAAGGTAA 89 ‡
JAK1 AATGGCTGTCATGGTCCAAT TACATCCCCTCCTCGCTTC 147 ‡ ‡
JAK2 CAGGAACAAGATGTGAACTGTTTC CCCATGCAGAGTCTTTTTCAG 52 ‡ ‡
JUN AGGATAGTGCGATGTTTCAGG GACTTCTCAGTGGGCTGTCC 65 ‡
KRT6B GGCCCTGGATGTGGAGAT TGACTTGTCCAACGCCTTC 67 ‡
MMP10 CAAAAGAGGAGGACTCCAACA TTCACATCCTTTTCGAGGTTG 61 ‡
NFKB1 CTGGCAGCTCTTCTCAAAGC TCCAGGTCATAGAGAGGCTCA 68 ‡ ‡
NFKBIZ TTGATACCATTAAGTGCCTAATTCA TTCTTCAGCTGCCAAATGC 32 ‡
NOTCH1 TCAATGAGTTCCAGTGCGAGT GCACACTCGTCCACATCGTA 105 ‡
PCYOX1 GCTCCGCCAGATAAAATCG CAAATTTCTGCCGCAGGT 66 ‡
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skin (PP_D0) vs. uninvolved psoriatic skin (PN_D0) of 
u.09, 11, 12 and 15 patients on day 0 (baseline). Also, 
lesions involved the psoriatic skin of patients following 
56 days (PP_D56) of 75 mg (u.09 and 12 patients) or 
150 mg (u.15 patient) genistein treatment handling or 
placebo (u.11 patient) vs. baseline (PP_D0); (blood sam-
ples) in u.09, 11, 12 and 15 patient’s PBCs vs. normal 
healthy people (control group) on day 0 (baseline), and 
in PBCs of patients following 56 days of 75 mg (u.09 
and 12 patients) or 150 mg (u.15 patient) genistein treat-
ment handling or placebo (u.11 patient) vs. baseline. Re-
sults were normalised to the expression of housekeep-
ing genes such as RPLP0 (ribosomal protein lateral stalk 
subunit P0) and YWHAZ (tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein zeta).
RESULTS
Alterations in gene expression in lesional psoriatic skin
In summary, we have analysed the activity of the 41 
genes indicated in Table 2. Due to the limited amount of 
isolated RNA from patient samples, studies on n=1 were 
performed. In general, in the 4 paired PP (lesional in-
volved psoriatic skin (PP_D0)) and PN (uninvolved pso-
riatic skin (PN_D0)) skin sections from 4 patients (u.09, 
11, 12 and 15) on day 0 (baseline), a rather clear separa-
tion of the PN_D0 samples from the PP_D0 samples 
was revealed (Table 3). On the basis of our criteria for 
differentially regulated transcripts, we identified that all 
41 genes differed in expression between the PP_D0 and 
PN_D0 samples, at least for one reference (RPLPO or 
YWHAZ) and minimum for the individual patient from 
the 4 subjects, analysed by real-time qRT-PCR (Table 3). 
Most of these genes (21 in total) were either down- or 
up-regulated, or unchanged, or had no data available, 
depending on the patient being analysed. Another 18 
mRNAs revealed up-regulated or unchanged records, or 
no data accessible, again depending on the subject being 
studied. Similarly, the activity of two other genes, namely 
FADS1 and TUFT1, was decreased or remained unaf-
fected depending on the patient being tested. Seven of 
the 41 modulated genes, visible among all four subjects, 
gained an increase in expression of as much as 10 to 20 
times. These included genes coding for the C-C motif 
chemokine ligand 4 (CCL4), anti-microbial peptides, in-
cluding human β-defensin 2 (DEFB4), and transcription 
factor forkhead box protein O1A (FOXO1), interleukin 
(IL) family members, such as interleukin 1B (IL1B) and 
8 (IL8), peptidase inhibitor 3 (PI3) and serpin family B 
member 3 (SERPINB3).
Genistein-responsive genes in skin biopsies
To investigate the impact of genistein on the gene 
activity profile of inflamed skin (PP), we compared the 
gene expression of skin biopsy samples at baseline (PP_
D0) and after 56 days (PP_D56) of therapy in the four 
patients, i.e. placebo, 75 or 150 mg genistein-treated. 
Again, as in the previous experiment, we also analysed 
the expression of 41 genes (Table 2), with n=1 only due 
to the restricted access to a larger quantity of material, 
with respect to reference genes, RPLPO and YWHAZ 
at a constant expression level, by using real-time qRT-
PCR. Response to genistein was associated with a sig-
nificant expression change in all 41 of the studied genes, 
irrespective of the patient, and for at least one reference 
(Table 3). As in the case of transcripts that differed in 
level between the PP_D0 and PN_D0 samples, a dif-
ferentiated profile of gene activity modulation was also 
observed, depending on the examined patient. In gen-
PI3 AGCCAGTCAAAGGTCCAGTC GCGCACCGGATCAAGATA 51 ‡ ‡
RHOB CCCCTGAGCATGCTTTTCT CGAGGGGAGTCGAACAGAC 5 ‡
RPLP0 TCGACAATGGCAGCATCTAC GCCAATCTGCAGACAGACAC 6 ‡ ‡
SERPINB3 CAACAAGCTCTTCGGAGAAAA TGGAGCATTTGCAAAATCAA 147 ‡
SIGIRR CTGGTGACCTTGCTGCTCT TGCACTTCTTTCCAAAAATCG 12 ‡ ‡
SOCS1 GGTCCCCCTGGTTGTTGTA GTAGGAGGTGCGAGTTCAGG 36 ‡ ‡
SOCS2 AGGCCTCACTGCAATTTGAT TGCAAAATATAAAATGCCCAAG 40 ‡
SP1 CTATAGCAAATGCCCCAGGT TCCACCTGCTGTGTCATCAT 131 ‡ ‡
STAT1 GGATTGAAAGCATCCTAGAACTCA GATGAAGCCCATGATGCAC 32 ‡
STAT3 TCCTGAAGCTGACCCAGGTA GGTCGTTGGTGTCACACAGAT 43 ‡ ‡
STAT4 ATCTGCCTCTATGGCCTGAC AATCATCACCACAGGCAATG 54 ‡
SYNCRIP CGATACCATCGGACAGGATT TCTGTAGCCATGTTTCCAGAGAT 30 ‡
TLR1 AGGGGACAATCCATTCCAA TTGGTCTATATTTTTGACAAATTCTCC 100 ‡ ‡
TLR4 CAAGATGCCCCTTCCATTT TCCTTAGGAATTAGCCACTAGACTTT 94 ‡
TNF CGGTGCTTGTTCCTCAGC GCCAGAGGGCTGATTAGAGA 12 ‡
TUFT1 GGAAAGTCCGGCAAATGATA GCGTCCTTTGACTGGATCAC 50 ‡
UST TGTGGACAGCATCCCAGAT TCATTCACGTTCAGCTTTGC 116 ‡
YWHAZ GATCCCCAATGCTTCACAAG TGCTTGTTGTGACTGATCGAC 102 ‡ ‡
ZNF12 GATCTGCCTCCGCTTTCAC ACAGCCACGTCCTTGAATG 65 ‡
ZNF483 ACTGGAAAACCTCAGGAACCTA CATGGCAATTCAACCCACT 33 ‡
‡points the analysis of a given gene in the skin or the PBC’ samples.
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eral, the smallest number of deregulated 
genes was identified for placebo (u.11). 
There were 14 genes in total, 12 with in-
creased and 2 with decreased expression. 
Studying carefully the gene expression lev-
els modulated in placebo, we found that 
stimulated CCL4, CXCL10, IL1A and IL6 
were down-regulated for all three patients 
treated with genistein. The other ten genes 
with modulated activity in placebo exhib-
ited a substantially varied pattern of ex-
pression in individual patients treated with 
genistein. In turn, the highest number of 
deregulated genes was observed for patient 
u.09, where all of the studied mRNAs, 
except for FABP5 and GJB2, revealed a 
change in the level at PP_D56 vs. PP_D0. 
Furthermore, in the case of both doses 
of 75 (u.09) and 150 (u.15) mg genistein-
treated patients (PP_D56 vs. PP_D0), most 
of the genes were down-regulated and 
only few showed accelerated activity once 
exposed to the tested isoflavone. How-
ever, the opposite trend was found for 
patient 12; that is, with a significant ma-
jority of up-regulated genes. In addition, 
the most significantly deregulated among 
all three patients in response to genistein 
(PP_D56 vs. PP_D0) was IL8, depending 
on the subject, from 3 to 5 times, exhibit-
ing either a decrease in mRNA level (for 
u.09 and 15, respectively) or an increase 
(around 6 times) in transcript amount (for 
u.12).
It should be noted that all 14 of the de-
regulated genes in u.11 placebo were found 
among the 38 transcripts (while for IL12A 
transcript we had no data available) which 
differed in level between the PP_D0 and 
PN_D0 samples (Table 3). Likewise, for 
genistein-treated patients, we identified a 
number of genes in a set of the transcripts 
that differed in levels between the PP_D0 
and PN_D0 samples. Correspondingly, we 
found that most of the genes (except for 
DEFB4A, FOSL1, KRT6B and PI3 in case 
of u.09; and SIGIRR, SP1, TLR1, TUFT1 
and UST in case of u.15), being deregu-
lated in PP vs. PN on day 0, showed a 
considerable reduction in activity after gen-
istein handling (D56). For u.12, we found 
11 of the 18 genes with modulated activ-
ity in the PP_D0 vs. PN_D0 were stimu-
lated in response to genistein (PP_D56 vs. 
PP_D0).
Changes in gene activity in the PBCs of 
psoriatic patients
To identify genes that were differentially 
regulated in the PBCs of u.09, 11, 12 and 
15 psoriatic patients, we examined the ex-
pression profile of the 45 genes listed in 
Table 2. In total, 16 out of 45 transcripts 
that differed in level between the psoriat-
ic patients’ and were varied from normal 
healthy control PBCs, in respect to RPL-
PO reference, and minimum for the indi-
vidual patient from the 4 subjects, analysed 
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by real-time qRT-PCR were affected (Table 4). Due to 
the limited amount of isolated RNA from patient sam-
ples, studies of n=1 were performed. In common be-
tween the four psoriatic patients when studying their 
PBC expression profiles, two genes revealed increased 
activity (i.e. CXCL10 and IL8, coding for the C-X-C 
motif chemokine ligand 10 and interleukin 8, respec-
tively), while another two were down-regulated (CCL2 
and CCL5, correspondingly coding for the C-C motif 
chemokine ligand 2 and C-C motif chemokine ligand 
5, respectively) (Table 4). The largest number of genes 
with modulated activity (14 genes) was observed for pa-
tient u.12 (treated with 75 mg genistein). Among them 8 
genes were up-regulated, as is the case for subject u.11. 
In turn, the smallest number of genes (i.e. 8) with the 
only single down-regulated gene had u.15 subject (taking 
150 mg genistein).
Modulated transcripts’ level in the PBCs in response to 
genistein
To study the effect of genistein on the gene expres-
sion profile of PBCs from psoriatic subjects treated with 
75 mg (u.09 and 12 patients) and 150 mg (u.15 patient) 
genistein or placebo (u.11 patient), we compared the 
mRNA levels at baseline (day 0) and after 56 days of 
therapy with respect to housekeeping RPLPO and YW-
HAZ genes and by real-time qRT-PCR (Fig. 1). Once 
more, as in the previous experiment, we also analysed 
the expression of 45 genes in total (Table 2), with n = 
1 only due to the restricted access to a larger quantity 
of material. The analysis revealed significant alterations 
in the activity of 36 of the 45 genes (Fig. 1). Then, we 
realised that there were 15 transcripts among those 36 
genes (except for SOCS2) that differed in levels between 
the psoriatic patient PBCs and those derived from nor-
mal healthy controls.
Wherein the largest number of genes (i.e. 23) with 
modulated activity was for u.11 (with 21 up-regulated 
and 2 down-regulated), the fewest genes (i.e. 7) were re-
ported for patient u.15 (Fig. 1). Of the 36 genes with 
modulated activity, only two, CCL2 and IL10, were de-
regulated, albeit diversified, in all 4 subjects tested. The 
most significantly stimulated were genes in patients treat-
ed with 75 mg genistein (i.e., IL17A app. 6-fold for u.09 
and IL10 app. 8-fold for u.12). On the other hand, the 
most considerably, as much as 3 to 6 times, down-reg-
ulated were IL6, IL11, IL17A and CXCL6 genes, with 
patient u.12 taking 150 mg genistein.
It is worth adding that, as in the case of gene activ-
ity analyses in skin specimens, where it was possible to 
determine a set of common genes between those with 
modulated activity in patients entering genistein tests 
and those that differed in level between the PP_D0 and 
PN_D0 samples, a similar circumstance was observed in 
PBC studies. Thus, 7 of the 23 genes with modulated 
activity in u.11 placebo (Fig. 1) were found among the 
11 transcripts that differed in levels between the psori-
atic patients’ and derived from normal healthy control 
PBCs (Table 4). Similarly, for genistein-treated patients 
we identified a number of genes in a set of the tran-
scripts that differed in level between the PBC of psori-
atic patients and normal healthy controls. Respectively, 
we found 7 of the 16 genes to have modulated activity 
in the case of u.09 (Fig. 1) from 11 transcripts (Table 4), 
11 of the 20 genes with modulated activity in the case of 
u.12 (Fig. 1) from 14 transcripts (Table 4), and 2 of the 
7 genes with modulated activity present in u.15 (Fig. 1) 
from 8 transcripts (Table 4). Remarkably, our results 
showed that the aberrant expression of some of these 
Table 4. List of 16 deregulated genes of the 45 studied in psoriatic PBCs, i.e. genes differentially expressed between u.09, 11, 12 and 
15 psoriatic patients and the normal healthy people on day 0 (baseline), analysed via real-time qRT-PCR. 
Alterations in transcript amount of the selected genes relate to an expression ratio greater than or equal to 1.3-fold and below or equal 
to 0.7, and with respect to RPLPO mRNA expression at a constant level. Due to the limited amount of isolated RNA from patient samples, 
studies on n=1 were performed.
Gene symbol
Fold change
u.09 (75 mg genistein) u.11 (placebo) u.12 (75 mg genistein) u.15 (150 mg genistein)
CCL2 0.5 0.5 0.2 0.8
CCL5 0.6 0.7 0.7 0.9
CXCL6 1.6 2.6 2.6 n.d.
CXCL10 1.8 2.2 3.5 4.6
IL1A 0.9 1.9 0.9 1.3
IL2 2.7 n.d. 4.4 n.d.
IL6 0.6 1.2 1.8 2.4
IL8 2.6 1.4 1.7 6.1
IL10 0.6 1.1 0.1 0.5
IL11 1.0 4.6 6.2 8.7
IL12A 0.4 0.4 0.2 0.9
IL17A 0.4 1.7 4.3 n.d.
JUN 1.0 1.8 2.4 5.4
SOCS2 0.6 0.7 0.8 0.8
STAT4 0.7 0.5 0.7 1.0
TLR1 0.9 1.5 0.7 2.6
n.d. shortcut stands for no data available.
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genes affected in psoriasis (Table 4) are improved by the 
action of genistein (Fig. 1).
Deregulated profile of gene expression in the skin 
specimens and the PBCs in response to genistein
Also noteworthy is the comparison of gene activity in 
the skin specimens and PBCs of u.09, 11, 12 and 15 pa-
tients participating in the genistein test (Fig. 2). Because 
the PBC analysis was basically representative of inflam-
mation-immune axis regulation genes, this comparison is 
just about these mRNAs. It was possible to produce a 
refined list of genes that were consistently differentially 
expressed in both PP skin and PBCs derived from all 
three patients treated with genistein, while not for pla-
cebo. Within this list, there are several genes that were 
deregulated; for patient u.09 we found 4 down-regulated 
transcripts (CCL4, IL10, NFKB1 and STAT3), for sub-
ject u.12 there were 2 decreased (CXCL10 and IL6) and 
1 stimulated in activity (IL1RN), and in the case of pa-
tient u.15, there was one with increased (IL8) and one 
reduced (IL10) mRNA level.
DISCUSSION
Various topical medications, phototherapy, and sys-
temic drugs are available to treat patients with pso-
riasis of varying disease severity. However, many stud-
ies are constantly performed to detect new therapeutic 
anti-psoriatic substances, which are verified in preclini-
cal laboratory tests and clinical phase trials (Bocheńska 
et al., 2017). This includes natural compounds which, as 
it turns out, are important in the treatment of psoriasis. 
They are the starting point for further analyses to im-
prove the health and quality of patients’ lives. Genistein 
turn out to be very important here. For example, Ito’s 
group investigated the topical application of Glyteer 
(GL, soybean) on a psoriatic model in mice (Ito et al., 
1992). Also, topical genistein was found to decrease 
psoralen-ultraviolet A (PUVA)-induced skin thickening 
and greatly reduce cutaneous erythema and ulceration 
in a dose-dependent manner (Shyong et al., 2002). Gen-
istein, a soy-derived molecule has attracted attention as a 
potent agent in the treatment of psoriasis, not only due 
to its anti-proliferative and immunosuppressive proper-
ties, but also as a mediator modulating the expression 
of various genes, whose products are involved among 
others in different phases of inflammation and prolifera-
tion (Smolińska et al., 2018). These statements resulted in 
proposing the performance of test with the use of gen-
istein for monitoring the activity of genes in the material 
derived from psoriatic patients.
Our study was designed to evaluate the impact of two 
dosing regimens of genistein at 75 or 150 mg per day 
administered orally on gene expression in patients with 
active mild to moderate chronic plaque psoriasis.
The exploratory objectives of this study were to 
evaluate gene expression levels in the four patients, i.e. 
placebo (u.11), 75 (u.09 and 12) or 150 (u.15) mg gen-
istein-treated. In total, with the criteria referred to in 
the Methods section, we selected 64 genes coding for 
proteins involved in lipid metabolism, antimicrobial de-
fences, epidermal differentiation and control of cutane-
ous vasculature, as well as immune mediators, for the 
analyses of 41 transcripts in the skin and 45 mRNAs in 
PBC samples, correspondingly (Table 2). Indeed, it has 
been shown in the literature that genistein influences 
the expression of inflammatory mediators, including the 
down-regulation of cytokine genes involved in mediat-
ing communication between cells (Mirahmadi et al., 2018; 
Figure 1. Alterations in the activity of 36 genes in PBCs from psoriatic subjects:
treated with 75 mg (u.09 and 12 patients) and 150 mg (u.15 patient) genistein or placebo (u.11 patient) on Day 56 vs. Day 0 (baseline, 
red line), analysed with the use of real-time qRT-PCR are referred to as 0.7≥FC≥1.3 (grey lines). The results are shown relative to the ex-
pression of the housekeeping genes RPLPO (grey bars) and YWHAZ (black bars). Due to the limited amount of isolated RNA from patient 
samples, studies on n=1 were performed.
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Vivatvakin et al., 2017). Initially, however, we dealt with 
the analysis of gene activity in those four patients be-
fore genistein administration. The study was in lesional 
involved psoriatic skin (PP_D0) vs. PN (uninvolved pso-
riatic skin (PN_D0), and in the PBCs derived from pso-
riatic patients vs. the normal healthy people. The results 
of these investigations revealed the clear separation of 
both the PN_D0 samples from the PP_D0 samples, as 
well as psoriatic PBC samples from the PBCs of normal 
healthy subjects (Table 3 and 4). In the next step, we 
compared the gene expression in the same four patients, 
either treated with 75 or 150 mg genistein, in relation 
to untreated placebo, again in both of the skin biopsy 
samples at baseline (PP_D0) and at 56 days (PP_D56) 
of therapy, and for the PBC samples at day 0 and 56. 
The outcomes of these works, described in detail in the 
Results section, allowed significant alterations in gene 
activity in both skin biopsies and PBCs under the in-
fluence of genistein to be noted (Table 3 and Fig. 1). 
It impairs the activity of certain genes which are over-
expressed in psoriasis, while stimulating the expression 
of other transcripts which are repressed in this derma-
tosis. Furthermore, the tissue-cross consideration regard-
ing the activity assessment of inflammation-immune axis 
genes in the material of the skin specimens and PBCs 
of our four patients joining the genistein test allow us 
to conclude that this isoflavone exhibits potential as an 
active anti-inflammatory agent, associated with its capac-
ity to modify the pattern of transcript levels across skin 
and blood cells (Fig. 2). Also, we found genes that were 
consistently differentially expressed both in PP skin and 
PBCs derived from all three patients treated with gen-
istein, while not for placebo.
Moreover, taking into consideration our previous re-
sults on the use of “psoriasis-like” HaCaT keratinocytes 
exposed to isoflavone genistein (Smolińska et al., 2018), 
we found that the 10 mRNAs (i.e. CCL4, CXCL1, 
CXCL10, IL1A, IL6, IL8, KRT6B, PI3, SIGIRR and 
ZNF483) studied in psoriatic skin patients were among 
the genes which were deregulated in the genistein-treated 
“psoriasis-like” epithelial cell line HaCaT. In turn, when 
analysing in detail the individual patients, we found 28 
transcripts deregulated regarding the modulation profile 
by genistein in patient u.09, 22 in patient u.12 and 14 
in patient u.15, as it was in case of “psoriasis-like” ke-
ratinocytes (see Figure 3 in Smolińska et al., 2018).
Figure 2. Genes identified as changed under studied conditions with corresponding overlap between the datasets (0.7≥FC≥1.3). 
Up- and down-regulated genes of the 64 analysed transcripts in lesional involved psoriatic skin (PP) and in peripheral blood cells (PBCs) 
of patients u.09, 11, 12 and 15 on day 0 (D0), and following 56 days (D56) of genistein treatment or placebo.
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To the point, we may conclude that, isoflavone gen-
istein, previously seen to be able to modulate the anti-
psoriatic members and anti-inflammatory mediators of 
inflammation, in this study showed some benefits to the 
aberrant expression of genes contributing to the progres-
sion of this dermatosis.
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